HomeCompareRSLS vs SCHD

RSLS vs SCHD: Dividend Comparison 2026

RSLS yields 51.02% · SCHD yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RSLS wins by $386.2K in total portfolio value
10 years
RSLS
RSLS
● Live price
51.02%
Share price
$3.92
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$415.3K
Annual income
$85,519.64
Full RSLS calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.46%
Share price
$30.48
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$425.95
Full SCHD calculator →

Portfolio growth — RSLS vs SCHD

📍 RSLS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSLSSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSLS + SCHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSLS pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSLS
Annual income on $10K today (after 15% tax)
$4,336.73/yr
After 10yr DRIP, annual income (after tax)
$72,691.69/yr
SCHD
Annual income on $10K today (after 15% tax)
$294.40/yr
After 10yr DRIP, annual income (after tax)
$362.06/yr
At 15% tax rate, RSLS beats the other by $72,329.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSLS + SCHD for your $10,000?

RSLS: 50%SCHD: 50%
100% SCHD50/50100% RSLS
Portfolio after 10yr
$222.1K
Annual income
$42,972.79/yr
Blended yield
19.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RSLS right now

RSLS
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-24.1
Piotroski
3/9
SCHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSLS buys
0
SCHD buys
0
No recent congressional trades found for RSLS or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSLSSCHD
Forward yield51.02%3.46%
Annual dividend / share$2.00$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$415.3K$29.0K
Annual income after 10y$85,519.64$425.95
Total dividends collected$332.9K$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: RSLS vs SCHD ($10,000, DRIP)

YearRSLS PortfolioRSLS Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$15,802$5,102.04$11,226$346.36+$4.6KRSLS
2$24,443$7,534.83$12,572$357.38+$11.9KRSLS
3$37,047$10,892.59$14,046$367.84+$23.0KRSLS
4$55,069$15,429.12$15,660$377.73+$39.4KRSLS
5$80,358$21,434.63$17,425$387.07+$62.9KRSLS
6$115,215$29,231.87$19,354$395.86+$95.9KRSLS
7$162,450$39,169.84$21,461$404.13+$141.0KRSLS
8$225,437$51,615.25$23,762$411.89+$201.7KRSLS
9$308,160$66,942.06$26,272$419.15+$281.9KRSLS
10$415,251$85,519.64$29,010$425.95+$386.2KRSLS

RSLS vs SCHD: Complete Analysis 2026

RSLSStock

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Full RSLS Calculator →

SCHDETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this RSLS vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSLS vs JEPIRSLS vs ORSLS vs KORSLS vs MAINRSLS vs VYMRSLS vs DGRORSLS vs VIGRSLS vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.